

Philip Livingston and Friedhelm Helling
U.S. Serial No.: 08/196,154
Filed: June 7, 1995
Page 2

On page 5, line 10, please delete "(b)" and insert --(Figure 2B)--.

On page 5, line 15, please delete "(a)" and insert --(Figure 3A)--.

On page 5, line 15, please delete "(b)" and insert --(Figure 3B)--.

On page 5, line 30, please delete "(a)" and insert --(Figure 6A)--.

On page 5, line 31, please delete "(b)" and insert --(Figure 6B)--.

On page 7, line 17, after "IgM", please insert --(Figure 10A)--.

On page 7, line 17, after "IgG", please insert --(Figure 10B)--.

On page 114, line 16, please wrap "(by logrank test). A similar trend was seen for survival ($p = .08$ by logrank test)." after ".02."

In the claims:

Please cancel claims 21-43 without prejudice.

Please add new claims 44-68:

31
--44. (New) A vaccine that effectively prevents cancer by stimulating or enhancing in a subject who is susceptible to cancer, production of an antibody which recognizes a ganglioside, comprising an amount of a ganglioside or an oligosaccharide portion thereof conjugated to an immunogenic protein effective to stimulate or enhance antibody production in the subject, an effective amount of adjuvant and a pharmaceutically acceptable vehicle.--